Sat.Sep 07, 2024 - Fri.Sep 13, 2024

article thumbnail

From Opioids to Cannabis: The Impact of Cannabis Rescheduling on Pharmacy Revenue Streams

Pharmacy Times

The DEA will have a hearing in December 2024 regarding the potential reclassification of cannabis to Schedule III, which could significantly impact the regulatory environment for pharmacies and their involvement in the cannabis market.

144
144
article thumbnail

Chronic Hand Eczema Studies Show Condition is Common, Burdensome

Drug Topics

LEO Pharma presented data from 2 of the largest multinational real-world studies on the prevalence, severity and treatment of chronic hand eczema at the European Society of Contact Dermatitis congress.

234
234
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Navigating Pharmacy School: Tips for Success

Pharmacy Is Right For Me

Written by: Toni Mikhael, PharmD, Touro College of Pharmacy Class of 2024. PGY-1 Pharmacy Resident, WellSpan Ephrata Community Hospital, Ephrata, PA Edited by: Anastasiya Shor, PharmD, BCPS Pharmacy school is a challenging but rewarding journey. As students embark on this demanding path, it becomes crucial to equip themselves with a toolkit for success.

article thumbnail

Japan approves updated Covid-19 vaccine to tackle JN.1 variant

Pharmaceutical Technology

Distribution of the self-amplifying mRNA vaccine Kostaive is set to align with a planned October 2024 Covid-19 vaccination campaign.

Vaccines 143
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

New Frontiers in Technology: AI Use in Clinical Trial Patient Recruitment in Health Systems

Pharmacy Times

AI is significantly enhancing the efficiency of identifying and enrolling patients.

169
169
article thumbnail

Lenacapavir for PrEP Demonstrates Strong Efficacy in Second Phase 3 Trial

Drug Topics

Gilead said data from the study will support global regulatory filings that the company plans to begin by the end of the year.

211
211

More Trending

article thumbnail

Half of women skip or delay care due to 'triple threat' of factors, report finds

Fierce Healthcare

Half of women in the U.S. skip or delay medical care due to the “triple threat” of affordability, access challenges and past negative experiences, a new Deloitte report finds. | The Deloitte report, based on a survey of more than 2,000 consumers, found that 50% of women report skipping or delaying medical care and are 35% more likely to skip care than men.

138
138
article thumbnail

Experts Develop Multimodal Approach for Treating Long COVID, Other Post-Acute Infectious Syndromes

Pharmacy Times

In the absence of a common treatment for long COVID, researchers from around the world documented the best currently available therapies.

article thumbnail

Discussing the Current Landscape of PBM Reform Legislation

Drug Topics

During an interview, Joseph Shields of TransparencyRx discusses the PBM legislation that is expected to move forward in Congress in the next few months.

211
211
article thumbnail

Medicine struggles to define chronic Lyme. Long Covid has only made it harder

STAT

Going to the doctor is already tricky enough for people with chronic symptoms of Lyme disease. Their concerns often dismissed by mainstream medicine, those patients now face an additional hurdle: ruling out long Covid.  The two illnesses — one seeping in over the course of decades and another suddenly springing to life on a massive scale — share many qualities, including being widely misunderstood.

144
144
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

UTHealth Houston collaborates with OpenAI to offer clinicians HIPAA-compliant ChatGPT solutions

Fierce Healthcare

UTHealth Houston unveiled a partnership with OpenAI on Friday to build and deploy algorithms for use in medical training and at the patient’s bedside. | UTHealth Houston, an academic medical center in Texas, is partnering with OpenAI to give clinicians, faculty and students access to ChatGPT tools to build custom, HIPAA-compliant AI solutions.

HIPAA 137
article thumbnail

Patients With Difficult-To-Treat Asthma Require Different Intervention Methods Based on Comorbidities

Pharmacy Times

To help with treatment response and compliance as well as optimize treatment, communication between patients and health care providers is necessary.

article thumbnail

Visual Art Therapy Significantly Improved Patients’ Mental Health Outcomes

Drug Topics

Researchers conducted a meta-analysis detailing previous patient outcomes in response to visual art therapy interventions.

200
200
article thumbnail

Biden administration finalizes rules to ensure insurers pay for mental health care 

STAT

The Biden administration on Monday announced it would finalize a highly anticipated proposal meant to force health insurers to cover mental health care on the same basis as physical health conditions.  It is the latest salvo in a long-running federal government effort to crack down on insurance plans skimping on treatment for conditions including anxiety, depression, and addiction.

Insurance 142
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer

Fierce Pharma

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific antibody’s potential as a new standard of care in non-small cell lung cancer.

138
138
article thumbnail

Remote Interventions From Pharmacists Shown to Improve Blood Glucose Control for Type 2 Diabetes

Pharmacy Times

Data show the value of the pharmacist is clear for patients with type 2 diabetes, as their role can have a significant impact on reductions in hemoglobin A1c.

139
139
article thumbnail

New Study Examines Potential of Oxytocin as Pain Management Adjunctive, Addiction Treatment

Drug Topics

The “cuddle hormone” plays a powerful role in human behavior and may be an additional option to treat pain and manage opioid addiction.

201
201
article thumbnail

Inquiry into unexplained bird flu case in Missouri broadens to a close contact

STAT

A close contact of the person in Missouri who had an unexplained H5N1 bird flu infection last month was also sick around the same time, but was not tested for influenza, the Centers for Disease Control and Prevention reported on Friday.  The CDC revealed the previously undisclosed information in FluView , its weekly report on influenza activity.

138
138
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Nationwide hospital mortality risk fell as acuity, volumes rose, report finds

Fierce Healthcare

Hospital patients’ risk of death has fallen substantially since the COVID-19 pandemic and the months preceding it, even as hospitals are treating more and sicker patients, according to a new report | An analysis of 715 hospitals' patient safety metrics showed that patients hospitalized in Q1 2024 were about 22% more likely to survive as compared to Q4 2019, after adjusting for illness severity.

Hospitals 131
article thumbnail

FDA Authorizes OTC Hearing Aid Software Compatible With Apple AirPods

Pharmacy Times

The Hearing Aid Feature can be customized to the user’s needs by amplifying sounds for individuals 18 years or older who have perceived mild to moderate hearing impairments.

FDA 139
article thumbnail

Community Pharmacist Education to Combat Vaccine Hesitancy

Drug Topics

Researchers explored an alternative pharmacist education intervention as a way of improving pharmacist-patient conversations and decreasing vaccine hesitancy among patients.

Vaccines 201
article thumbnail

STAT+: Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial

STAT

SAN DIEGO — For years, Merck’s drug Keytruda has dominated cancer immunotherapy, racking up dozens of approvals, extending the lives of patients, and bringing in billions of dollars to the pharma giant. But detailed data presented by Summit Therapeutics on Sunday demonstrated that the company’s experimental therapy has done what no other has done before: beat Keytruda in a head-to-head late-stage trial in lung cancer.

132
132
article thumbnail

Gridlock over schedule II telehealth prescribing could impede extension of pandemic-era flexibilities

Fierce Healthcare

Over 300 organizations sent letters to the White House and Congress on Tuesday asking them to extend telehealth controlled substance prescribing rules for an additional two years. | Stakeholders that support the prescription of all controlled substances via telehealth are fighting an uphill battle to get the pandemic-era prescribing flexibilities extended.

article thumbnail

Increased Psychological, Cardiovascular Risks in Relatives of Patients With Cancer

Pharmacy Times

Parents of children with cancer had the highest risk of developing mental illness and cardiovascular diseases.

139
139
article thumbnail

Semaglutide Therapy Associated With Fewer COVID-19–Related Deaths

Drug Topics

Data from the SELECT clinical trial were analyzed to evaluate the role of semaglutide therapy on all-cause, cardiovascular, and non-cardiovascular mortality during the COVID-19 pandemic.

200
200
article thumbnail

STAT+: With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights

STAT

On Sunday, a small biotech company called Summit Therapeutics won a remarkable victory, saying its experimental drug outperformed Merck’s Keytruda , the world’s best-selling drug, in non-small cell lung cancer, the disease that represents Keytruda’s biggest market. By itself, Summit’s victory would be a dramatic story, although not an unheard of one in the unpredictable world of biotechnology.

131
131
article thumbnail

Mercer: Employer benefit costs set to rise by more 5% in 2025 for 3rd straight year

Fierce Healthcare

Employers are bracing for a third straight year with health benefit costs increasing more than 5%, according to a new report from Mercer. | Employers are bracing for a third straight year with health benefit cost increases of more than 5%, according to a new report from Mercer.

128
128
article thumbnail

HIV Infections Significantly Reduced With Twice-Yearly Lenacapavir in Cisgender Men, Gender-Diverse Participants

Pharmacy Times

These results build off the PURPOSE 1 trial, contributing to the wealth of evidence surrounding lenacapavir’s positive effects in patients with HIV.

139
139
article thumbnail

Education Is Crucial to Close Gaps in Colorectal Cancer Risk Awareness

Drug Topics

The #MyCRChistory campaign encourages the public to share their family history of colorectal cancer.

191
191
article thumbnail

STAT+: A new drug offers a rare option for brain cancer treatment — and inspires hopes for more

STAT

For more cancer coverage, sign up for STAT’s pop-up newsletter focused on this weekend’s European Society for Medical Oncology conference, one of the biggest oncology meetings of the year. Details here. When Rachel Guberman found out she had brain cancer, she did so much reading and Googling about the disease that she joked she had reached the end of the internet.

article thumbnail

AppliedVR's flagship VR device for chronic lower back pain now in network for Highmark members

Fierce Healthcare

Pittsburgh-based Highmark has signed on as AppliedVR's first commercial payer partner, making its flagship VR device for chronic lower back pain a covered treatment for more than 4 million plan mem | Pittsburgh-based Highmark has signed on as AppliedVR's first commercial payer partner, making its flagship VR device for chronic lower back pain a covered treatment for more than 4 million plan members.

129
129
article thumbnail

FDA Approves Guselkumab for Treatment of Ulcerative Colitis

Pharmacy Times

Guselkumab (Tremfya; Johnson & Johnson) is the first and only approved fully human and dual-acting monoclonal antibody blocking interleukin-23 and binding to CD64 receptors.

FDA 139
article thumbnail

Small Doses: September 2 to September 6

Drug Topics

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

185
185